Endogenous opioid inhibition of chronic low-back pain influences degree of back pain relief after morphine administration

Regional Anesthesia and Pain Medicine

Volumn 39, Issue 2, 2014, Pages 120-125

  Bruehl, Stephen ^a   Burns, John W ^b   Gupta, Rajnish ^a   Buvanendran, Asokumar ^c   Chont, Melissa ^a   Schuster, Erik ^b   France, Christopher R ^d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

^d OHIO UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDORPHIN; MORPHINE; NALOXONE; PLACEBO;

ADULT; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG RESPONSE; FEMALE; HUMAN; LOW BACK PAIN; MALE; MCGILL PAIN QUESTIONNAIRE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PAIN; PAIN INTENSITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REDUCTION; VISUAL ANALOG SCALE; VOMITING; YOUNG ADULT;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOW BACK PAIN; MALE; MIDDLE AGED; MORPHINE; OPIOID PEPTIDES; PAIN MEASUREMENT;

EID: 84894421647     PISSN: 10987339     EISSN: 15328651     Source Type: Journal    
DOI: 10.1097/AAP.0000000000000058     Document Type: Article

References (25)

1. Bruehl S, Apkarian AV, Ballantyne JC, et al. Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges. J Pain. 2013;14:103-113.
2. Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66:355-474.
3. Benedek G, Szikszay M. Sensitization or tolerance to morphine effects after repeated stresses. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9:369-380.
4. Bodnar RJ, Kelly DD, Steiner SS, Glusman M. Stress-produced analgesia and morphine-produced analgesia: lack of cross-tolerance. Pharmacol Biochem Behav. 1978;8:661-666.
5. Fazli-Tabaei S, Yahyavi SH, Alagheband P, et al. Cross-tolerance between antinociception induced by swim-stress and morphine in formalin test. Behav Pharmacol. 2005;16:613-619.
6. Bruehl S, Burns JW, Gupta R, et al. Endogenous opioid function mediates the association between laboratory-evoked pain sensitivity and morphine analgesic responses. Pain. 2013;154:1856-1864.
7. Bruehl S, McCubbin JA, Harden RN. Theoretical review: altered pain regulatory systems in chronic pain. Neurosci Biobehav Rev. 1999;23:877-890.
8. Corder G, Doolen S, Donahue RR, et al. Constitutive μ-opioid receptor activity leads to long-term endogenous analgesia and dependence. Science. 2013;341:1394-1399.
9. Martikainen IK, Peciña M, Love TM, et al. Alterations in endogenous opioid functional measures in chronic back pain. J Neurosci. 2013;33:14729-14737.
10. Martin WR. Drugs five years later: naloxone. Ann Intern Med. 1976;85:765-768.
11. Bruehl S, Burns JW, Chung OY, Chont M. Interacting effects of trait anger and acute anger arousal on pain: the role of endogenous opioids. Psychosom Med. 2011;73:612-619.
12. Lewis J, Mansour A, Khachaturian H, Watson SJ, Akil H. Opioids and pain regulation. Pain Headache. 1987;9:129-159.
13. Fillingim RB, Ness TJ, Glover TL, et al. Morphine responses and experimental pain: sex differences in side effects and cardiovascular responses but not analgesia. J Pain. 2005;6:116-124.
14. Berkowitz BA, Ngai SH, Hempstead J, Spector S. Disposition of naloxone: use of a new radioimmunoassay. J Pharmacol Exp Ther. 1975;195:499-504.
15. Melzack R. The short form of the McGill Pain Questionnaire. Pain. 1987;30:191-197.
16. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psych. 1986;51:1173-1182.
17. Sobel ME. Effect analysis and causation in linear structural equation models. Psychometrika. 1990;55:495-515.
18. Parks EL, Geha PY, Baliki MN, Katz J, Schnitzer TJ, Apkarian AV. Brain activity for chronic knee osteoarthritis: dissociating evoked pain from spontaneous pain. Eur J Pain. 2011;15:843.e1-843.e14.
19. Edwards RR, Haythornthwaite JA, Tella P, Max MB, Raja S. Basal heat pain thresholds predict opioid analgesia in patients with postherpetic neuralgia. Anesthesiology. 2006;104:1243-1248.
20. France CR, Al'Absi M, Ring C, France JL, et al. Assessment of opiate modulation of pain and nociceptive responding in young adults with a parental history of hypertension. Biol Psychol. 2005;70:168-174.
21. France CR, Al'Absi M, Ring C, France JL, Harju A, Wittmers LE. Nociceptive flexion reflex and pain rating responses during endogenous opiate blockade with naltrexone in healthy young adults. Biol Psychol. 2007;75:95-100.
22. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10:663-672.
23. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65:529-538.
24. Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008;28:20-29.
25. Raehal KM, Bohn LM. The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology. 2011;60:58-65.